Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis.

Camilo E FadulYang Mao-DraayerKathleen A RyanRandolph J NoelleHeather A WishartJacqueline Y ChannonIsaac R KasperBrant J OliverDaniel W MielcarzLloyd H Kasper

Published in: Neurology(R) neuroimmunology & neuroinflammation (2021)

This study provides Class IV evidence on the safety, pharmacokinetics, and immune effects of an mAb to CD40L in patients with RRMS.

Keyphrases

multiple sclerosis
nk cells
white matter